Other
Gain on sale of equity security
Biogen Gain on sale of equity security decreased by 145.7% to -$3.2M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 40.7%, from -$5.4M to -$3.2M.
Analysis
StatementIncome Statement
SectionOther
First reportedQ2 2018
Last reportedQ1 2026Apr 29, 2026
Metric ID:
other_equity_securities_fv_ni_realized_gain_loss_578c3bHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $400K | -$2.7M | -$200K | $700K | -$500K | $1.6M | -$700K | $4.4M | $4.9M | $600K | -$10.9M | -$5.4M | $0 | $7M | -$3.2M |
| QoQ Change | — | -775.0% | +92.6% | +450.0% | -171.4% | +420.0% | -143.8% | +728.6% | +11.4% | -87.8% | <-999% | +50.5% | +100.0% | — | -145.7% |
| YoY Change | — | — | — | +75.0% | +81.5% | +900.0% | -200.0% | +980.0% | +206.3% | +185.7% | -347.7% | -210.2% | -100.0% | +164.2% | +40.7% |
Range-$10.9M – $7M
CAGR+81.1%
Avg YoY Growth+148.0%
Median YoY Growth+78.2%
Frequently Asked Questions
- What is Biogen's gain on sale of equity security?
- Biogen (BIIB) reported gain on sale of equity security of -$3.2M in Q1 2026.
- How has Biogen's gain on sale of equity security changed year-over-year?
- Biogen's gain on sale of equity security increased by 40.7% year-over-year, from -$5.4M to -$3.2M.